ClinicalTrials.gg
CompletedNCT03140241Updated May 21, 2018

Pain Assessment by Pupil Dilation Reflex (PDR) and Pupillary Pain Index (PPI) in Response to Noxious Stimulation in Anesthetized Adults

An interventional study of PDR measurement in Nociceptive Pain and Monitoring, Intraoperative, sponsored by University Hospital, Antwerp. Completed at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-05-21.

Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

After conduction a pilot study, pupillary dilation reflex (PDR) is measured in response to nociceptive stimulation perioperatively.

Read the detailed description

An infrared camera of the video pupillometer measures the pupillary dilation reflex (PDR) in response to incremental nociceptive stimuli. The PDR is a robust reflex, even in patients under general anesthesia, and may provide a potential evaluation of the autonomous nociceptive circuit. American Society of Anesthesiologists (ASA) classification I or II patients undergoing elective surgery under general anesthesia are recruited. Enrolled patients perioperative undergo PDR measurement at 2 different standardized times (before and after opioid administration) generated by an inbuilt pupillary pain index (PPI) protocol. PPI, as a surrogate for nociception includes noxious stimulations from 10 up to 60 milli ampere (mA) until pupil dilation is larger than 13% from baseline diameter. Therefore, no inappropriate high stimulation is executed.

02

Conditions studied

  • Nociceptive Pain
  • Monitoring, Intraoperative

Browse trials for

03

In context

Nociceptive Pain

96 studies on the registry are indexed under Nociceptive Pain; 18 are open to participants now.

This study's enrollment of 34 is below the median of 61 across 62 interventional studies indexed under Nociceptive Pain.

Browse Nociceptive Pain studies →

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 243 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled abdominal or gynecological surgery

Exclusion criteria

Exclusion Criteria:

  • History of eye deformity, invasive ophthalmologic surgery
  • Known cranial nerve(s) deficit
  • Infection of the eye
  • Predicted difficult airway management (DAF Guidelines)
  • Chronic opioid use (>3 months)
  • Ongoing treatment with beta-blockers, dopamine antagonists, topical atropine
  • Preoperatively administrated benzodiazepins or antiemetics
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    PDR measurement

    Two measurements of PDR perioperatively before and after opioid administration

    Procedure: PDR measurement

Interventions

  • ProcedurePDR measurement

    PDR measurement at two standardized times perioperatively: 1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50 2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth

    Also known as: PPI assessment

06

What researchers measure

Primary outcomes

  1. Stimulation Intensity

    Necessary stimulation intensity to dilate the pupil more than 13%

    Time frame: During perioperative period

Secondary outcomes

  1. Pupillary Pain Index score

    Device specific PPI score defined in accordance to stimulation intensity necessary for pupil dilation more than 13%

    Time frame: During perioperative period

  2. Systolic blood pressure

    Hypertension as a common used parameter for perioperative nociceptive assessment

    Time frame: During PDR measurements

  3. Heart rate

    Tachycardia as a common used parameter for perioperative nociceptive assessment

    Time frame: During PDR measurements

07

Study locations

1 site
  • University hospital Antwerp
    Edegem, Antwerp 2650, Belgium
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2017, 1 month.

Of 37 non-industry interventional studies with no phase under Nociceptive Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 32. This study's 1 month is below that.

Counting every sponsor, half of 42 studies reached it within 8 months; a quarter within 3 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2017
First posted
May 4, 2017
StartActual
May 7, 2017
Primary completionActual
Jun 29, 2017
CompletionActual
Jul 20, 2017
Last update
May 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03140241
Responsible party
Davina Wildemeersch (MD, University Hospital, Antwerp) — Principal investigator
First posted
May 4, 2017
Start date
May 7, 2017
Primary completion
Jun 29, 2017
Completion
Jul 20, 2017
Last update
May 21, 2018

Study contacts

Michiel Baeten, MD
principal investigator · University Hospital, Antwerp
Natasja Peeters, MD
principal investigator · University Hospital, Antwerp
Vera Saldien, MD
study chair · University Hospital, Antwerp

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion